PTC Therapeutics, Inc. (PTCT) Borrowing debt
- Total debt · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30..
- Net cash · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30..
- Debt / assets · latest quarter: Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30..
Borrowing debt
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total debt · latest quarter (USD) | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Net cash · latest quarter | (m) | Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Debt / assets · latest quarter | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Borrowing debt due within one year | 55.45M USD | Long-term Debt, Current Maturities |
| Borrowing debt due after one year | 535.52M USD | Long-term Debt, Excluding Current Maturities |
| Commercial paper | (m) | |
| Cash and current securities | 2.23B USD | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current |
| Borrowing debt | (m) | Long-term Debt, Current Maturities · Long-term Debt, Excluding Current Maturities |
| Total assets | 3.25B USD | Assets |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total debt | Net cash / debt | Borrowing debt due within one year (USD) | Borrowing debt due after one year (USD) | Commercial paper (USD) | Cash and current securities (USD) | Total assets (USD) | Debt / assets |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $55.45M | $535.52M | (m) | $2.23B | $3.25B | (m) |
| 2026-03-31 | (m) | (m) | $286.94M | (m) | (m) | $1.89B | $2.87B | (m) |
| 2025-12-31 | (m) | (m) | $286.63M | (m) | (m) | $1.95B | $2.90B | (m) |
| 2025-09-30 | (m) | (m) | $286.32M | (m) | (m) | $1.69B | $2.64B | (m) |
| 2025-06-30 | (m) | (m) | (m) | $286.01M | (m) | $1.99B | $2.63B | (m) |
| 2025-03-31 | (m) | (m) | (m) | $285.71M | (m) | $2.03B | $2.66B | (m) |
| 2024-12-31 | (m) | (m) | (m) | $285.41M | (m) | $1.14B | $1.71B | (m) |
| 2024-09-30 | (m) | (m) | (m) | $285.11M | (m) | $1.01B | $1.84B | (m) |
| 2024-06-30 | (m) | (m) | (m) | $284.81M | (m) | $1.09B | $1.92B | (m) |
| 2024-03-31 | (m) | (m) | (m) | $284.51M | (m) | $884.81M | $1.79B | (m) |
| 2023-12-31 | (m) | (m) | (m) | $284.21M | (m) | $876.74M | $1.90B | (m) |
| 2023-09-30 | (m) | (m) | (m) | $573.17M | (m) | $294.81M | $1.26B | (m) |
| 2023-06-30 | (m) | (m) | (m) | $572.64M | (m) | $337.94M | $1.34B | (m) |
| 2023-03-31 | (m) | (m) | (m) | $572.09M | (m) | $286.30M | $1.61B | (m) |
| 2022-12-31 | (m) | (m) | (m) | $571.72M | (m) | $410.70M | $1.71B | (m) |
| 2022-09-30 | (m) | (m) | (m) | $282.75M | (m) | $288.43M | $1.58B | (m) |
| 2022-06-30 | (m) | (m) | $149.91M | $282.46M | (m) | $505.55M | $1.80B | (m) |
| 2022-03-31 | (m) | (m) | $149.72M | $282.18M | (m) | $587.79M | $1.80B | (m) |
| 2021-12-31 | (m) | (m) | $149.54M | $281.89M | (m) | $773.38M | $1.94B | (m) |
| 2021-09-30 | (m) | (m) | $149.36M | $281.60M | (m) | $867.94M | $2.01B | (m) |
| 2021-06-30 | (m) | (m) | (m) | $430.50M | (m) | $947.08M | $2.06B | (m) |
| 2021-03-31 | (m) | (m) | (m) | $430.04M | (m) | $988.41M | $2.11B | (m) |
| 2020-12-31 | (m) | (m) | (m) | $309.14M | (m) | $1.10B | $2.21B | (m) |
| 2020-09-30 | (m) | (m) | $0.00 | $302.97M | (m) | $1.14B | $2.18B | (m) |
| 2020-06-30 | (m) | (m) | $18.33M | $297.03M | (m) | $498.89M | $1.48B | (m) |
| 2020-03-31 | (m) | (m) | $20.00M | $294.57M | (m) | $595.86M | $1.55B | (m) |
| 2019-12-31 | (m) | (m) | $20.00M | $293.86M | (m) | $686.56M | $1.62B | (m) |
| 2019-09-30 | (m) | (m) | $20.00M | $293.15M | (m) | $708.65M | $1.64B | (m) |
| 2019-06-30 | (m) | (m) | $20.00M | $135.68M | (m) | $363.54M | $1.29B | (m) |
| 2019-03-31 | (m) | (m) | $16.67M | $138.47M | (m) | $407.16M | $1.28B | (m) |
| 2018-12-31 | (m) | (m) | $11.67M | $141.35M | (m) | $227.59M | $1.12B | (m) |
| 2018-09-30 | (m) | (m) | $6.67M | $144.26M | (m) | $249.40M | $1.03B | (m) |
| 2018-06-30 | (m) | (m) | $1.67M | $147.20M | (m) | $296.11M | $511.77M | (m) |
| 2018-03-31 | (m) | (m) | (m) | $146.88M | (m) | $178.27M | $379.41M | (m) |
| 2017-12-31 | (m) | (m) | (m) | $144.97M | (m) | $191.25M | $391.65M | (m) |
| 2017-09-30 | (m) | (m) | (m) | $143.09M | (m) | $169.31M | $367.72M | (m) |
| 2017-06-30 | (m) | (m) | (m) | $141.24M | (m) | $181.07M | $383.08M | (m) |
| 2017-03-31 | (m) | (m) | (m) | $99.89M | (m) | $202.58M | $248.65M | (m) |
| 2016-12-31 | (m) | (m) | (m) | $98.22M | (m) | $231.67M | $269.35M | (m) |
| 2016-09-30 | (m) | (m) | (m) | $96.56M | (m) | $248.34M | $288.18M | (m) |
| 2016-06-30 | (m) | (m) | (m) | $94.94M | (m) | $272.89M | $305.56M | (m) |
| 2016-03-31 | (m) | (m) | (m) | $93.37M | (m) | $298.71M | $335.23M | (m) |
| 2015-12-31 | (m) | (m) | (m) | $94.61M | (m) | $338.93M | $368.04M | (m) |
| 2014-03-31 | (m) | (m) | $12.00K | (m) | (m) | $246.59M | $255.84M | (m) |
| 2013-12-31 | (m) | (m) | $48.62K | (m) | (m) | $142.47M | $151.90M | (m) |
| 2013-09-30 | (m) | (m) | $84.23K | (m) | (m) | $157.23M | $167.24M | (m) |
| 2013-06-30 | (m) | (m) | $2.75M | (m) | (m) | $165.68M | $175.47M | (m) |
| 2012-12-31 | (m) | (m) | $4.44M | $438.81K | (m) | (m) | $13.07M | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |